| Absci (NASDAQ:ABSI) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $7.00 price target on the stock. This represents a 155.9% upside from the current price of $2.74. |
| argenex (NASDAQ:ARGX) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $700.00 price target on the stock. This represents a 29.2% upside from the current price of $541.85. |
| Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $250.00 price target on the stock. This represents a 44.1% upside from the current price of $173.55. |
| Axsome Therapeutics (NASDAQ:AXSM) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $190.00 price target on the stock. This represents a 82.6% upside from the current price of $104.05. |
| BioMarin Pharmaceutical (NASDAQ:BMRN) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $97.00 price target on the stock. This represents a 67.4% upside from the current price of $57.94. |
| Certara (NASDAQ:CERT) is now covered by analysts at Morgan Stanley. They set an "equal weight" rating and a $16.00 price target on the stock. This represents a 40.1% upside from the current price of $11.42. |
| Disc Medicine (NASDAQ:IRON) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $85.00 price target on the stock. This represents a 58.9% upside from the current price of $53.49. |
| Kymera Therapeutics (NASDAQ:KYMR) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $70.00 price target on the stock. This represents a 56.5% upside from the current price of $44.74. |
| Primoris Services (NASDAQ:PRIM) is now covered by analysts at Janney Montgomery Scott. They set a "buy" rating and a $102.00 price target on the stock. This represents a 23.0% upside from the current price of $82.91. |
| Recursion Pharmaceuticals (NASDAQ:RXRX) is now covered by analysts at Morgan Stanley. They set an "equal weight" rating and a $5.00 price target on the stock. This represents a 4.1% downside from the current price of $5.22. |
| Sana Biotechnology (NASDAQ:SANA) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $12.00 price target on the stock. This represents a 292.7% upside from the current price of $3.06. |
| Schrodinger (NASDAQ:SDGR) is now covered by analysts at Morgan Stanley. They set an "equal weight" rating and a $28.00 price target on the stock. This represents a 32.7% upside from the current price of $21.11. |
| Telix Pharmaceuticals (NASDAQ:TLX) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $23.00 price target on the stock. This represents a 42.4% upside from the current price of $16.16. |
